[HTML][HTML] Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV …
A Oliva, F Cogliati Dezza, F Petrucci… - Clinical and …, 2023 - Springer
Patients with haematological malignancies (HM) and SARS-CoV-2 infection present a
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study
A Oliva, FC Dezza, F Petrucci, FE Romani… - 2023 - researchsquare.com
Purpose. Patients with hematological malignancies (HM) and SARS-CoV-2 infection present
a higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
a higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study
A Oliva, FC Dezza, F Petrucci… - Clinical and …, 2023 - pubmed.ncbi.nlm.nih.gov
Patients with haematological malignancies (HM) and SARS-CoV-2 infection present a
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
[PDF][PDF] Outcome of COVID‑19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM‑COV 2.0 …
A Oliva, FC Dezza, F Petrucci, FE Romani… - 2023 - scienceopen.com
Patients with haematological malignancies (HM) and SARS-CoV-2 infection present a
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
[HTML][HTML] Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV …
A Oliva, FC Dezza, F Petrucci, FE Romani… - Clinical and …, 2023 - ncbi.nlm.nih.gov
Patients with haematological malignancies (HM) and SARS-CoV-2 infection present a
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study
A Oliva, F COGLIATI DEZZA, F Petrucci… - CLINICAL AND …, 2023 - iris.uniroma1.it
Patients with haematological malignancies (HM) and SARS-CoV-2 infection present a
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
[PDF][PDF] Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 …
A Oliva, FC Dezza, F Petrucci, FE Romani… - academia.edu
Purpose. Patients with hematological malignancies (HM) and SARS-CoV-2 infection present
a higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
a higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study.
A Oliva, F Petrucci, FE Romani… - Clinical and …, 2023 - europepmc.org
Patients with haematological malignancies (HM) and SARS-CoV-2 infection present a
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
[PDF][PDF] Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 …
A Oliva, FC Dezza, F Petrucci, FE Romani… - scholar.archive.org
Purpose. Patients with hematological malignancies (HM) and SARS-CoV-2 infection present
a higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
a higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
[PDF][PDF] Outcome of COVID‑19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM‑COV 2.0 …
A Oliva, FC Dezza, F Petrucci, FE Romani… - 2023 - iris.uniroma1.it
Patients with haematological malignancies (HM) and SARS-CoV-2 infection present a
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …
higher risk of severe COVID-19 and mortality. The aim of the study was to investigate …